Skip to content

A multicentre, prospective controlled study of the clinical efficacy of bladder preservation in patients with bladder cancer, based on artery intubation chemotherapy combined with bladder organoid culture and drug sensitivity test

A multicentre, prospective controlled study of the clinical efficacy of bladder preservation in patients with bladder cancer, based on artery intubation chemotherapy combined with bladder organoid culture and drug sensitivity test

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092585
Enrollment
Unknown
Registered
2024-11-19
Start date
2024-12-15
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder tumor

Interventions

Experimental group:cTURBT, artery intubation chemotherapy and intravesical chemotherapy instillation
Control group:Radical resection of the bladder

Sponsors

The first affiliated hospital of soochow university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. MIBC, T2a-T2b, N0, M0 disease. 2. NMIBC, T1G3 which is multiple, recurrent, and >=3cm diameter. (multiple is defined as two or more locations) 3. NMIBC, BCG-relapsing or BCG-unresponsive. 4. NMIBC, T1G3 with CIS at bladder or prostatic urethra. 5. Age >=18, male or female. 6. ECOG score 0-1. 7. Patients are able to comply with research and follow-up procedures. 8. Patients have the ability to understand and voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous occurrence or concurrent presence of other malignant tumors. 2. Existence of serious or uncontrollable systemic diseases. 3. A female patient who plans a pregnancy or breast-feeding. 4. Hearing loss >Level 2. 5. Heart failure NYHA grading >Grade III. 6. Peripheral neuropathy >Grade 2. 7. There is a serious or uncontrollable systemic disease.

Design outcomes

Primary

MeasureTime frame
OS(Overall Survival);DFS(Disease-free Survival);PFS(Progression Free Survival);

Secondary

MeasureTime frame
DSS(Disease-specific Survival);Success rate of bladder preservation;Salvage radical resection rate;QOL(Quality Of Life);

Countries

China

Contacts

Public ContactYuhua Huang

The first affiliated hospital of soochow university

sdfyy_hyh@163.com+86 189 1375 2992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026